Segment Disclosure (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Net Loss Related To Segment Expenses

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Year Ended December 31,
	2024			2023			2022
Revenue	$	—		$	—		$	9,434
Less:
Direct external research and development costs
Azetukalner		106,806			89,303			37,367
XEN 496		—			5,152			14,765
Pre-clinical, discovery and other programs		21,546			15,552			12,711
Personnel-related expenses		68,340			47,739			36,088
Stock-based compensation		50,717			32,372			20,376
Other research and development costs		11,232			9,560			7,274
Other general and administrative costs		20,657			14,376			9,996
Interest income		(41,943	)		(27,620	)		(8,713	)
Other segment items(1)		(3,025	)		(4,041	)		4,943
Net loss		(234,330	)		(182,393	)		(125,373	)

(1)Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).